97.00Open97.00Pre Close0 Volume0 Open Interest390.00Strike Price0.00Turnover85.41%IV-15.78%PremiumDec 20, 2024Expiry Date136.93Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9924Delta0.0015Gamma1.85Leverage Ratio-0.0134Theta-0.0282Rho-1.83Eff Leverage0.0111Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet